These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10659050)

  • 1. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity.
    Lopalco L; Pastori C; Cosma A; Burastero SE; Capiluppi B; Boeri E; Beretta A; Lazzarin A; Siccardi AG
    AIDS Res Hum Retroviruses; 2000 Jan; 16(2):109-15. PubMed ID: 10659050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
    J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    Barassi C; Soprana E; Pastori C; Longhi R; Buratti E; Lillo F; Marenzi C; Lazzarin A; Siccardi AG; Lopalco L
    J Virol; 2005 Jun; 79(11):6848-58. PubMed ID: 15890924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD4 antibodies are associated with HIV-1 seroconversion and may be detectable before anti-HIV-1 antibodies. The Multicenter AIDS Cohort Study.
    Keiser P; Keay S; Wasserman S; Wecksler W
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1919-27. PubMed ID: 1489580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses.
    Leith JG; Clark DA; Matthews TJ; Rosenthal KL; Luscher MA; Barber BH; MacDonald KS
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):957-65. PubMed ID: 14678602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
    Bomsel M; Pastori C; Tudor D; Alberti C; Garcia S; Ferrari D; Lazzarin A; Lopalco L
    AIDS; 2007 Jan; 21(1):13-22. PubMed ID: 17148963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretory IgA specific for MPER can protect from HIV-1 infection in vitro.
    Benjelloun F; Dawood R; Urcuqui-Inchima S; Rochereau N; Chanut B; Verrier B; Lucht F; Genin C; Paul S
    AIDS; 2013 Jul; 27(12):1992-5. PubMed ID: 23696073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals.
    Burastero SE; Gaffi D; Lopalco L; Tambussi G; Borgonovo B; De Santis C; Abecasis C; Robbioni P; Gasparri A; Lazzarin A; Celada F; Siccardi AG; Beretta A
    AIDS Res Hum Retroviruses; 1996 Mar; 12(4):273-80. PubMed ID: 8906987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket.
    Pastori C; Barassi C; Piconi S; Longhi R; Villa ML; Siccardi AG; Clerici M; Lopalco L
    J Biol Regul Homeost Agents; 2000; 14(1):15-21. PubMed ID: 10763886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.
    Wilfingseder D; Spruth M; Ammann CG; Döpper S; Speth C; Dierich MP; Stoiber H
    Int Arch Allergy Immunol; 2003 May; 131(1):62-72. PubMed ID: 12759492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein.
    Carrillo J; Restrepo C; Rallón NI; Massanella M; del Romero J; Rodríguez C; Soriano V; Clotet B; Benito JM; Blanco J
    AIDS; 2013 Jun; 27(9):1375-85. PubMed ID: 23945502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
    Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L
    New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection.
    Beretta A; Furci L; Burastero S; Cosma A; Dinelli ME; Lopalco L; DeSantis C; Tambussi G; Carrow E; Sabbatani S; Clerici M; Lazzarin A; Siccardi AG
    Immunol Lett; 1996 Jun; 51(1-2):39-43. PubMed ID: 8811343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1.
    Babaahmady K; Bergmeier LA; Lehner T
    AIDS; 2008 Jul; 22(11):1267-76. PubMed ID: 18580605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection.
    Schønning K; Joost M; Gram GJ; Machuca R; Nielsen C; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):195-202. PubMed ID: 9665495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.
    Mazzoli S; Lopalco L; Salvi A; Trabattoni D; Lo Caputo S; Semplici F; Biasin M; Bl C; Cosma A; Pastori C; Meacci F; Mazzotta F; Villa ML; Siccardi AG; Clerici M
    J Infect Dis; 1999 Sep; 180(3):871-5. PubMed ID: 10438383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.